255 related articles for article (PubMed ID: 19325240)
41. Oxidative stress induced by iron released from transferrin in low pH peritoneal dialysis solution.
Yamaji Y; Nakazato Y; Oshima N; Hayashi M; Saruta T
Nephrol Dial Transplant; 2004 Oct; 19(10):2592-7. PubMed ID: 15292463
[TBL] [Abstract][Full Text] [Related]
42. Time to reconsider saline as the ideal rinsing solution during abdominal surgery.
Połubinska A; Winckiewicz M; Staniszewski R; Breborowicz A; Oreopoulos DG
Am J Surg; 2006 Sep; 192(3):281-5. PubMed ID: 16920418
[TBL] [Abstract][Full Text] [Related]
43. Increased dialysate levels of phospholipids containing unsaturated fatty acid are associated with increased peritoneal transport rate.
Zhe XW; Gao F; Nie HG; Tian XK; Chen W; Liu HW; Lindholm B; Axelsson J; Wang T
Am J Nephrol; 2008; 28(6):1007-13. PubMed ID: 18648191
[TBL] [Abstract][Full Text] [Related]
44. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis.
Hasuike Y; Moriguchi R; Hata R; Miyagawa K; Kuragano T; Aizawa M; Yamamoto S; Yanase K; Izumi M; Tanimoto T; Nakanishi T
Am J Nephrol; 2007; 27(6):622-9. PubMed ID: 17851230
[TBL] [Abstract][Full Text] [Related]
45. Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients.
Guz G; Glorieux GL; De Smet R; Waterloos MA; Vanholder RC; Dhondt AW
Nephrol Dial Transplant; 2006 Oct; 21(10):2834-40. PubMed ID: 16762960
[TBL] [Abstract][Full Text] [Related]
46. Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy.
Zager RA
Kidney Int; 2005 Oct; 68(4):1533-42. PubMed ID: 16164630
[TBL] [Abstract][Full Text] [Related]
47. Long-term follow-up of body size indices, residual renal function, and peritoneal transport characteristics in continuous ambulatory peritoneal dialysis.
Twardowski ZJ; Moore HL; Prowant BF; Satalowich R
Adv Perit Dial; 2009; 25():155-64. PubMed ID: 19886338
[TBL] [Abstract][Full Text] [Related]
48. Role of peritoneal mesothelial cells and fibroblasts in the synthesis of hyaluronan during peritoneal dialysis.
Breborowicz A; Wisniewska J; Polubinska A; Wieczorowska-Tobis K; Martis L; Oreopoulos DG
Perit Dial Int; 1998; 18(4):382-6. PubMed ID: 10505559
[TBL] [Abstract][Full Text] [Related]
49. Sulodexide modulates the dialysate effect on the peritoneal mesothelium.
Misian M; Baum E; Breborowicz A
J Physiol Pharmacol; 2019 Dec; 70(6):. PubMed ID: 32203941
[TBL] [Abstract][Full Text] [Related]
50. Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients: a prospective, open-label study.
Pai AB; Norenberg J; Boyd A; Raj D; Chan LN
Clin Ther; 2007 Dec; 29(12):2699-705. PubMed ID: 18201586
[TBL] [Abstract][Full Text] [Related]
51. Dialysate CA125 levels in stable peritoneal dialysis patients.
Okada T; Nakao T; Matsumoto H
Clin Nephrol; 1999 Jan; 51(1):65-6. PubMed ID: 9988153
[No Abstract] [Full Text] [Related]
52. Safety and usefulness of intravenous iron sucrose in the management of preoperative anemia in patients with menorrhagia: a phase IV, open-label, prospective, randomized study.
Kim YH; Chung HH; Kang SB; Kim SC; Kim YT
Acta Haematol; 2009; 121(1):37-41. PubMed ID: 19332985
[TBL] [Abstract][Full Text] [Related]
53. The TGF-beta-induced gene product, betaig-h3: its biological implications in peritoneal dialysis.
Park SH; Choi SY; Kim MH; Oh EJ; Ryu HM; Kim CD; Kim IS; Kim YL
Nephrol Dial Transplant; 2008 Jan; 23(1):126-35. PubMed ID: 17704110
[TBL] [Abstract][Full Text] [Related]
54. Intraperitoneal hyaluronan administration in conscious rats: absorption, metabolism, and effects on peritoneal fluid dynamics.
Breborowicz A; Polubinska A; Pawlaczyk K; Kuzlan-Pawlaczyk M; Moberly J; Martis L; Oreopoulos D
Perit Dial Int; 2001; 21(2):130-5. PubMed ID: 11330555
[TBL] [Abstract][Full Text] [Related]
55. [Effect of dialysates on ultrastructure of mouse peritoneal mesothelium].
Li J; Zhong H; Zhang K; Chen Y; Xu P
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1999 Jun; 21(3):208-13. PubMed ID: 12569655
[TBL] [Abstract][Full Text] [Related]
56. Changes of surface tension of dialysate depending on its composition in continuous ambulatory peritoneal dialysis.
Jeleniewicz R; Majdan M; Buraczyńska K; Portala P; Majdan M
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):290-5. PubMed ID: 12898852
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of intravenous iron sucrose therapy in a group of children with iron deficiency anemia.
Pinsk V; Levy J; Moser A; Yerushalmi B; Kapelushnik J
Isr Med Assoc J; 2008 May; 10(5):335-8. PubMed ID: 18605353
[TBL] [Abstract][Full Text] [Related]
58. Two different modalities of iron gluconate i.v. administration: effects on iron, oxidative and inflammatory status in peritoneal dialysis patients.
de Vecchi AF; Novembrino C; Lonati S; Ippolito S; Bamonti F
Nephrol Dial Transplant; 2007 Jun; 22(6):1709-13. PubMed ID: 17298995
[TBL] [Abstract][Full Text] [Related]
59. Association between nitric oxide and oxidative stress in continuous ambulatory peritoneal dialysis patients with peritonitis.
Duranay M; Yilmaz FM; Yilmaz G; Akay H; Parpucu H; Yücel D
Scand J Clin Lab Invest; 2007; 67(6):654-60. PubMed ID: 17852815
[TBL] [Abstract][Full Text] [Related]
60. Glucose dialysate induces mitochondrial DNA damage in peritoneal mesothelial cells.
Ishibashi Y; Sugimoto T; Ichikawa Y; Akatsuka A; Miyata T; Nangaku M; Tagawa H; Kurokawa K
Perit Dial Int; 2002; 22(1):11-21. PubMed ID: 11929138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
